Skip to content
Menu

Zevra Therapeutics, Inc. ZVRA

Full chart Compare
Set alert

Price alert · ZVRA

All alert types
9.07 USD -0.21 (-2.26%)

Regular-session close

8.93 -0.14 -1.55%

Pre-market · Nov 20, 5:13 AM ET

9.00 Day range 9.50
8.01 52-week range 15.04
YTD
+1.23%
1 year
+0.22%

5D -2.32 (-19.85%)

91011ThuFriMonTueWed9.37
Market cap
539.71M
Revenue (ttm)
24.49M
EPS (ttm)
1.22
Shares out
53.38M
P/E ratio
7.43
Forward P/E
-22.00
YTD return
+1.23%
1-year return
+0.22%
Volume
670.29K
Avg volume
951.49K
Open
9.24
Previous close
9.28
Day's range
9.00 – 9.50
52-week range
8.01 – 15.04
Beta
1.93
Price target
20.00 (+120.5%)

Key statistics

50-day average
8.69
200-day average
6.59
Enterprise value
422.45M
Price / sales
18.70
Price / book
6.54
Revenue growth
27.60%
Total cash
89.38M
Total debt
59.93M
Return on equity
-130.67%
Short % of float
8.09%

Fundamental scorecard

17 of 25 checks passed on ZVRA’s reported financials

ValueGrowthProfitabilityHealthDividend

17of 25 checks passed

  • Value 4 of 5
  • Growth 4 of 5
  • Profitability 4 of 5
  • Financial health 5 of 5
  • Dividend 0 of 5

Statements to Sep 30, 2026.

Financials — quick view

All financials
ZVRA Revenue — quarterly 37.76M
ZVRA Net income — quarterly 19.21M
ZVRA EPS — quarterly 0.31

Earnings

ZVRA recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Nov 12, 2024Sep 1, 2024-0.44-0.69-0.25-56.82%
Aug 13, 2024Jun 1, 2024-0.47-0.48-0.01-2.13%
May 8, 2024Mar 1, 2024-0.49-0.40+0.09+18.37%
Mar 28, 2024Dec 1, 2023-0.20-0.40-0.20-100.00%
Nov 7, 2023Sep 1, 2023-0.29-0.40-0.11-37.93%
Aug 14, 2023Jun 1, 2023-0.39-0.15+0.24+61.54%

Upgrades / downgrades

ZVRA analyst upgrades and downgrades
DateFirmActionFromTo
Nov 20, 2024HC Wainwright & Co.reitBuyBuy
Nov 14, 2024Canaccord GenuitymainBuyBuy
Oct 11, 2024Cantor Fitzgeraldreit—Overweight
Oct 7, 2024Guggenheiminit—Buy
Oct 1, 2024Cantor Fitzgeraldreit—Overweight
Sep 30, 2024HC Wainwright & Co.reitBuyBuy

About Zevra Therapeutics, Inc.

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.

Sector
Healthcare
Industry
Biotechnology
Country
United States
Website
zevra.com

News

Your note

Sign in to keep a note on ZVRA — it syncs with the Stock Master app.

Institution ownership

ZVRA institution ownership
Holder% heldSharesValueReported
Woodline Partners LP93.83%4,048,65334.74MSep 29, 2024
Blackrock Inc.72.35%3,121,75926.78MSep 29, 2024
Nantahala Capital Management, LLC67.77%2,924,02125.09MSep 29, 2024
Vanguard Group Inc63.88%2,756,06123.65MSep 29, 2024
FMR, LLC53.61%2,313,20219.85MSep 29, 2024
Altium Capital Management, LP39.40%1,700,00014.59MSep 29, 2024

Fund ownership

ZVRA fund ownership
Holder% heldSharesValueReported
Vanguard Total Stock Market Index Fund38.65%1,667,44314.31MSep 29, 2024
iShares Russell 2000 ETF25.11%1,083,4929.30MOct 30, 2024
Vanguard Extended Market Index Fund17.13%739,1746.34MSep 29, 2024
Fidelity Advisor Equity Growth Fund15.29%659,8205.66MOct 30, 2024
Variable Insurance Products Fund-Growth Portfolio14.88%642,1005.51MOct 30, 2024
Fidelity Small Cap Index Fund9.96%429,6003.69MAug 30, 2024